PMID- 32296330
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic 
      Disorder: A Meta-Analysis of Randomized Controlled Trials.
PG  - 275
LID - 10.3389/fphar.2020.00275 [doi]
LID - 275
AB  - OBJECTIVE: To explore the short-term efficacy and tolerability of paroxetine in 
      the treatment of panic disorder in adults. METHODS: Multiple electronic databases 
      were searched to find randomized controlled trials (RCTs) on paroxetine and panic 
      disorder. The primary efficacy outcomes were: the mean change compared to the 
      baseline in the total number of full panic attacks, Clinical Global 
      Impression-Severity of Illness (CGI-S) score, and the proportion of participants 
      with zero full panic attacks and with a 50% or greater reduction in the number of 
      full panic attacks. The tolerability outcomes included withdrawal rate and the 
      incidence of adverse events (AEs). RESULTS: 13RCTs were included. The pooled 
      analyses showed patients who received paroxetine experienced greater improvements 
      in the number of full panic attacks (total: MD=-1.96, 95%CI -3.45 to -0.47, 
      P=0.010; >/=50% reduction: OR=1.66, 95%CI 1.08 to 2.55, P=0.02; zero full panic 
      attacks: OR=1.70, 95%CI 1.42 to 2.03, P < 0.00001) and CGI-S (MD=-0.37, 95%CI 
      -0.74 to -0.01, P=0.05) than placebo. There was no evident difference in the 
      total withdrawal rate (OR=0.91, 95%CI 0.76 to 1.08, P=0.26) and withdrawal rate 
      due to AEs (OR=1.29, 95%CI 0.97 to 1.72, P=0.07) between the two groups. 
      Withdrawal rate due to lack of efficacy or relapse (OR=0.44, 95%CI 0.31 to 0.63, 
      P < 0.00001) and the incidence of serious AEs (OR=0.42, 95%CI 0.23 to 0.79, 
      P=0.007) in the paroxetine group was lower than the placebo group. Meanwhile, the 
      incidence of any treatment-emergent adverse events (TEAEs) (OR=1.32, 95%CI 1.05 
      to 1.64, P=0.02) in the paroxetine group was higher in comparison with the 
      placebo. CONCLUSIONS: Paroxetine is an effective and well-tolerated short-term 
      treatment for adults with panic disorder.
CI  - Copyright (c) 2020 Zhang, Wang, Cui, Gao, Wang, Tan and Fang.
FAU - Zhang, Beilin
AU  - Zhang B
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Wang, Chao
AU  - Wang C
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Cui, Lexiang
AU  - Cui L
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Gao, Jiguo
AU  - Gao J
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Wang, Chenglin
AU  - Wang C
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Tan, Xiangyu
AU  - Tan X
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
FAU - Fang, Shaokuan
AU  - Fang S
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, China.
LA  - eng
PT  - Systematic Review
DEP - 20200331
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7136560
OTO - NOTNLM
OT  - efficacy
OT  - meta-analysis
OT  - panic disorder
OT  - paroxetine
OT  - tolerability
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
PMCR- 2020/03/31
CRDT- 2020/04/17 06:00
PHST- 2019/11/21 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
PHST- 2020/03/31 00:00 [pmc-release]
AID - 10.3389/fphar.2020.00275 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Mar 31;11:275. doi: 10.3389/fphar.2020.00275. eCollection 
      2020.